Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.1950 |
| Open | 0.1800 |
| Bid | 0.1400 x N/A |
| Ask | 0.1700 x N/A |
| Day's Range | 0.1800 - 0.1800 |
| 52 Week Range | 0.1150 - 0.2500 |
| Volume | |
| Avg. Volume | 26,302 |
| Market Cap | 12.569M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, November 30, 2022, at 10:15am Eastern standard time. Rakovina invites individual and institutional investors as well as advisors and
- GlobeNewswire
Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the quarter ended September 30, 2022 and provided a corporate update. Corporate Update Rakovina Therapeutics has continued to communicate progress in the Company’s research and development programs through presentations at pee
- GlobeNewswire
Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma
Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), today announced publication of a scientific article on the anti-cancer activity of the Company’s novel dual PARP-HDAC inhibitor in models of Ewing sarcoma. The manuscript entitled “A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma”, indicate a bene
